Peer-reviewed veterinary case report
Blood test markers linked to prognosis in dogs with lymphoma
By Jae-Hyeon Im et al.·Published in Veterinary and Comparative Oncology·2023·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of serum interleukin 2 receptor and beta-2-microglobulin as prognostic factors for canine lymphoma: a pilot study.
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma were tested for two substances in their blood, interleukin 2 receptor (IL-2R) and beta-2-microglobulin (B2M), to see if they could help predict how the disease would progress. The study found that dogs diagnosed with lymphoma had high levels of IL-2R, while B2M levels were not significantly elevated. However, in dogs that relapsed after treatment, both IL-2R and B2M levels were higher, with B2M being particularly useful for predicting relapses. This suggests that monitoring these substances could help veterinarians assess the prognosis and manage treatment for dogs with lymphoma.
People also search for: dog lymphoma prognosis · canine lymphoma treatment · high IL-2R levels in dogs · dog cancer relapse signs
Abstract
Interleukin 2 receptor (IL-2R) is released from activated T cell lymphocytes and related to proliferation of B cells and T cells. Beta-2-microglobulin (B2M) is synthesized from all nucleated cells and constitutes a major histocompatibility complex class I antigen. In human medicine, high concentrations of these two factors have been found to be related to prognosis in aggressive non-Hodgkin's lymphoma (NHL). In this pilot study, we aimed to assess the correlation between the serum concentration of IL-2R and B2M and the diagnosis and prognosis of canine lymphoma. This study included 8 healthy dogs and 17 dogs with lymphoma. To measure the serum concentration of IL-2R and B2M, a commercial enzyme-linked immunosorbent assay was used. In dogs with lymphoma, IL-2R concentrations were significantly high at the time of diagnosis, but B2M concentrations were not. In relapsed dogs, both IL-2R and B2M concentrations were significantly higher than those in the control and chemotherapy response groups. When the serum concentrations of IL-2R and B2M during chemotherapy were monitored in four relapsed dogs, B2M levels were more closely related with relapse. This study demonstrated that serum IL-2R and B2M concentration can be a diagnostic or prognostic tool for canine lymphoma. Monitoring of serum B2M concentration seems to be useful for predicting relapse.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/36635848